Smooth muscle tumors associated with X-linked Alport syndrome: Carrier detection in females  by Dahan, Karin et al.
Kidney International, Vol. 48 (1995), pp. 1900—1906
Smooth muscle tumors associated with X-linked Alport
syndrome: Carrier detection in females
KARIN DAHAN,1 LAURENCE HEIDET, JING ZHOU, G. ME'ITLER, KATHLEEN A. LEPPIG,
WILLEM PROESMANS, ALBERT DAVID, BERNARD ROUSSEL, J.G. MONGEAU, J.M.D GOULD,
JEAN-PIERRE GRUNFELD, MARIE-CLAIRE GUBLER, and CORINNE ANTIGNAC
INSERM U423, Hôpital Necker-Enfants Malades, Paris, France; Department of Nephrology, Brigham and Woman's Hospital, Boston, Massachusetts,
USA; Department of Pediatric Children s Hospital of Eastern Ontario, Ottawa, Canada; Division of Medical Genetics, Children Hospital and Medical
Center, Seattle, Washington, USA; Department of Pediatrics, University Hospital, Leuven, Belgium; Service de Pediatric, Centre Hospitalier, Nantes,
France; Service de Pediatric, American Memorial Hospital, Reims, France; Service de Pediatrie, Hôpital Sainte Justine, Montreal, Canada; Department of
Child Health, The Ipswich Hospital, Ipswich, England, United Kingdom; and Département de Nephrologie, Hôpital Necker-Enfants Malades, Université
René Descartes, Paris, France
Smooth muscle tumors associated with X-linked Alport syndrome:
Carrier detection in females. X-linked Alport syndrome (AS) associated
with diffuse esophageal leiomyomatosis (DL) has been reported to be due
to deletions removing the 5' ends of both the COL4A5 and COL4A6
genes, encoding the aS and a6 chains of type IV collagen, respectively,
whereas a variety of mutations in COL4A5 has been identified in patients
with AS alone. Here we report three additional DL-AS patients who also
display deletions removing the 5' ends of both COL4A5 and COL4A6
genes. Furthermore, we tracked the mutation in 15 females belonging to
six DL-AS families by gene copy number determination. We found that,
like AS, DL is transmitted as an X-linked dominant trait but, contrary to
AS, DL is fully penetrant and completely expressed in females. These
results are in agreement with our previous work suggesting that DL could
be due to a dominant effect of an abnormal a6(IV) collagen chain. Finally,
we have detected a similar deletion of the COL4A5 and COL4A6 genes in
a DL affected female who showed no sign of nephropathy, demonstrating
the AS carrier status of this DL patient. These results emphasize the
importance of molecular analysis of female DL patients for genetic
counseling.
Alport syndrome (AS) is a hereditary nephropathy character-
ized by progressive hematuric nephritis with ultrastructural
changes of the glomerular basement membrane (GBM). In the
majority of the families, AS segregates as an X-linked dominant
trait. Mutations in the COL4A5 gene, which encodes the a5 chain
of type IV collagen, a normal component of the GBM, have been
reported in several X-linked AS families [1—3]. The penetrance
and expressivity of the renal disease is complete in males but not
in females, in agreement with the predicted effect of random
inactivation of a mutant X-chromosomal gene [4]. The association
of AS with diffuse esophageal leiomyomatosis (DL), and in some
cases with congenital cataracts, has also been reported [5—21]. DL
is due to benign smooth muscle cell proliferation within the
esophageal wall [22]. Other smooth muscle tumors, involving the
tracheobronchial tree and, in females, the genital tract, are
frequent in DL-AS patients [7]. Deletions removing both the 5'
ends of the COL4A5 gene and the recently discovered COL4A6
gene [201, encoding the novel a6 type IV collagen chain, have
been identified in eight unrelated patients with DL-AS [18, 20,
21]. The COL4A5 and COL4A6 genes are located head-to-head
on chromosome X, at Xq22, with an intergenic region spanning
only 450 base pairs [20, 231. Furthermore, COL4A6 transcripts
have been detected in fetal esophagus, adult kidney [201 and
human lens epithelial cells in culture [23]. These data suggested
that a null mutation of COL4A6 or both COL4A5 and COL4A6
could be responsible for the leiomyomatosis process. However,
three patients with AS but without leiomyomatosis, and bearing
deletions in COL4A5 as well as large deletions in COL4A6, have
recently been reported [3, 211, raising the question of the pen-
etrance of DL in DL-AS patients.
In this report, we extended the study of the molecular defect in
DL-AS to three additional patients and again found in each
patient a deletion involving the 5' ends of both the COL4A5 and
COL4A6 genes. We also tracked the mutation in 15 females
belonging to six families with DL-AS. We found that, like AS, DL
is a dominant X-linked affection, but, contrary to the renal
disease, DL is completely penetrant and fully expressed in fe-
males. Finally, we studied the genotype of a female patient
presenting with DL without any symptoms of nephropathy and
showed that this patient also had a defect in the COL4A5 gene,
and was thus carrying AS, a finding of major importance for
genetic counseling.
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Methods
Patients
Blood samples were collected from two unrelated male (EO,
RD) and one female (HL) patients with the DL-AS association,
and from a 43-year-old female patient (MC) with DL alone.
DNAs from 15 female family members of six patients with DL-AS,
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two described above (RD, HL) and four (HE, TP, BD and JT) in
whom deletions involving both COL4A5 and COL4A6 have been
previously reported [21], were also studied in order to determine
their carrier status. Among these 15 female relatives, seven
belonging to four families (JT, BD, RD, and HE) have clinical
symptoms of esophageal involvement whereas eight are appar-
ently unaffected. The clinical data of patients EU [101, HE [161,
TP [13] and JT [6] and their affected relatives have been previ-
ously reported.
The two male patients (RD and EU) have hematuria (discov-
ered at 11 and 2 years, respectively), typical glomerular ultrastruc-
tural features of Alport syndrome and sensorineural hearing loss.
The former developed end-stage renal failure at 25. The latter has
normal GFR, but is only 16. The nine DL-AS affected females
[two probands (HE, HL) and seven family members] have hema-
tuna, and renal biopsies performed in the two probands showed
alternating thick and thin GBM segments. GFR is normal in all
but one, who reached ESRD at age 32 (family RD, patient 1113).
None of them suffers from hearing loss. Conversely, the eight
asymptomatic females had normal results on urinary analysis.
The tumoral syndrome includes severe esophageal involvement
in all DL-AS patients. The two male patients (EU and RD) have
suffered from recurrent vomiting, dysphagia and epigastric pain
since the ages of 5 and 12. They underwent surgical treatment at
8 and 16. The nine female patients with DL-AS displayed the
same kind of digestive symptoms and they all underwent subtotal
esophagectomy between the ages of 2 and 40. Several of them also
have respiratory symptoms (dyspnea, wheezing, asthma, bronchi-
tis), inferring the likely involvement of the tracheobronchial tree.
Three of five adult females have genital leiomyomas with diffuse
clitoridal and vulvar hypertrophy (kindred BD, patient 111; kin-
dred RD, patient 1113; kindred iT, patient 12). One patient
developed an adenocarcinoma of the pancreas when she was 48.
The two male patients as well as two females (kindred BD, patient
Ill; kindred RD, patient 1113) were found to have bilateral
posterior cataracts. On the contrary, there was no clinical evi-
dence of esophageal, genital or ocular involvement in the eight
unaffected female members of the six families (mean age of 39
years).
The female DL patient (MC) underwent esophagectomy at the
age of 19 years. She also presented with multiple genital and
urethral leiomyomas. She had a hysterectomy for multiple uterine
leiomyomas, and underwent surgery several times for labial and
urethral leiomyomas as well as clitoridal hypertrophy. At 43 years
of age, she was admitted to hospital with urinary tract infections;
laboratory investigations showed normal renal function with nei-
ther hematuria nor proteinuria. No renal biopsy was performed.
However, audiometry revealed bilateral high-tone sensorineural
deafness, without any obvious cause. Bilateral cataracts were
observed at that time. She also had chronic obstructive lung
disease for years. She died a few months later from acute
respiratory failure probably due to a tracheobronchial leiomyo-
matosis. Her mother was also affected with DL and died at 28
years of age during esophageal surgery. No other family member
had a history of deafness or renal or digestive involvement.
Southern blot analyses
Southern blotting analyses were performed as described [18],
using several probes spanning the COL4A5 and COL4A6 eDNA,
a COL4A6 genomic probe and an rDNA probe. Five COL4A5
eDNA probes were used: from the 5' end to the 3' end, JZ4,
HT14-2, HT14-3 [241, PL31 and PC4b [25] which encode
COL4A5 exons 1 to 9, 17 to 27, 28 to 32, 35 to 50 and 51,
respectively (Fig. 1A). Two probes derived from JZ3 [20] were
used to span the 5' end of COL4A6: a 145 bp BsrI fragment
corresponding to exons 3 and 4, named JZ3FR145, and a 133 bp
MspA3 fragment corresponding to exons 1 and 2, named
JZ3FR133. The genomic probe LA226-EH is an EcoRI-HindIII
genomic fragment containing the first exon of COL4A6 and 198
bp of the intergenic region [20]. The probes JZ4, JZ3 and
LA226-EH all hybridize to an 1.4-kb EcoRI fragment and a 2-kb
PstI fragment containing both COL4A5 and COL4A6 exons 1.
The ribosomal DNA mouse fragment spanning the 18S rRNA
gene (amino acid residues I to 1644), the sequence of which is
extremely homologous among the mouse, rat, rabbit and human
[26], was used as a reference for quantitation of gene copy
number. It reveals an 8-kb EcoRI band and two PstI fragments of
8 and 12 kb.
Scanning densitometiy
To determine the gene copy number, Southern blots were
successively hybridized with the probes tested and with the non-X
chromosome rDNA probe. Superimposed autoradiograms were
analyzed by scanning densitometry (Hoefer Scientific Instruments
GS300). The peak areas corresponding to each hybridization
signal were calculated by electronic integration. The values for
normal control subjects and for patients were estimated through
two or three independent determinations. As the two PstI frag-
ments detected by the rDNA probe give a signal of the same
intensity (data not shown), either of them could be used as a
control. Different ratios have been deduced from these values
[27]. The R ratio was obtained by dividing the intensity of the
fragments detected by COL4A5 or COL4A6 probes by the
intensity of the fragments detected with the control probe. The
P/C ratio was obtained by dividing the ratio (R) of the patient (P)
by the ratio of the control (C) individual (normal female patient).
A P/C ratio around 1 means that the patient has 2 alleles of the
fragment of the gene detected by the probe used, whereas a P/C
ratio around 0.5 means that the patient DNA has only one copy of
the allele.
Results
COL4A5 and COL4A6 deletions in male patients
Southern blot analysis revealed rearrangements in both the
COL4A5 and the COL4A6 genes of the two male patients, RD
and EU. EcoRI-digested DNAs hybridized to JZ3FR133 lacked
the 1.4 kb fragment containing exon I of both COL4A5 and
COL4A6 and the 5,6 kb fragment corresponding to COL4A6 exon
2, whereas they both displayed the normal 5.1 and 9 kb fragments
containing exons 4 and 3 of COL4A6 when hybridized to
JZ3FR145, demonstrating that the COL4A6 breakpoints are
located in intron 2 (Figs. 1 and 2A). EcoRI-digested DNAs
hybridized to JZ4 also lacked the 1.4 kb band (Fig. 2B), whereas
the 3.6, 5.5 and 10 kb bands, which contain exons 3, 5—9 and 2,
respectively, were present without novel restriction fragments.
Hybridization to the other COL4A5 probes showed normal
patterns.
The patterns observed are consistent with deletions involving
exons 1 and 2 of COL4A6 and exon 1 of COL4A5 in both patients.
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Fig. 1. Schematic diagram of the COL4A5-COL4A6 deletions in probands. A. Schematic representation of the COL4A5-COL4A6 locus, showing the
location of the different probes used for Southern blot analysis. The first exons of the COL4A5 and COL4A6 genes are shown as black and striped boxes,
respectively. E: EcoRI restriction sites. B. Deletions in DL-AS patients RD, EO, and HL and in DL-patient MC. Symbols are: (LI) deleted regions;
hatched boxes, ambiguities in mapping the deletion boundaries; (•) non-deleted regions. C. Previously reported patient deletions (patients 1 and 2 have
been reported in [201, and patients 3 to 9 in [211.
Deletions in female probands
The DL-AS female patient, HL, as well as the DL patient, MC,
were studied with the COL4A5 cDNA probes JZ4 and Pc4b, and
with the genomic probe LA226-EH by scanning densitometry
(Table 1).
Southern blots of PstI-digests from both patients revealed a
reduction in the intensity of 2-kb PstI fragments with the
LA226-EH genomic probe. Furthermore, with JZ4, the intensity
of the 2-kb PstI fragment was reduced in both patients, whereas
the 1.7-kb PstI band spanning COL4A5 exon 3 was present with
normal intensity. The COL4A5 exon 2 PstI fragment has not yet
been determined and thus could not be scanned. The 2.1 kb
fragment which hybridizes to Pc4b and spanns exons 48 to 51 of
COL4A5 displayed a normal signal (P/C ratio around 1). Thus,
the Pc4b probe could also be used as an internal control, which
seems appropriate here since it detects bands in the same range of
size as those tested. As shown in Table 1, similar results were
obtained whatever the control probe used.
These results show that the deletions in the two patients
encompass the first exons of both COL4A5 and COL4A6 and do
not extend to COL4A5 exon 3, but may include exon 2 (Fig. 1B).
Given the high background obtained with the COL4A6 probes, it
was not possible to quantify the signals of the bands correspond-
ing to exons 2 to 4 of COL4A6 detected by the JZ3FR133 and
JZ3FR145 probes. This prevented us from studying the extent of
the deletion downstream from COL4A6 exon 1.
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Table 1. Densitometry values obtained by scanning of the female
proband PstI Southern blots
Tested
probe rDNA R P/C
Tested
probe Pc4b R P/C
LA226-EH
C 12049 13940 0.86
MC 3610 7889 0.46 0.53
HL 7258 15385 0.47 0.55
Pc4b
C 2549 13940 0.18
MC 1877 7889 0.24 1.33
HL 3110 15385 0.20 1.11
JZ4 exon I
C 12292 5937 2.07 12292 3055 4.02
MC 5189 4140 1.25 0.60 5189 2120 2.45 0.61
HL 6424 7502 0.86 0.42 6424 3961 1.62 0.40
JZ4 exon 3
C 10016 5937 1.69 10016 3055 3.28
MC 8212 4140 1.98 1.17 8212 2120 3.87 1.18
HL 11586 7502 1.54 0.91 11586 3961 2.92 0.89
Tracking the mutation in families
Since the rearrangements observed in the six probands do not
lead to altered-size fragments, we used densitometry to track the
deletion in their families (Fig. 3 and Table 2). EcoRI or PstI
digested DNAs were probed with the LA226-EH genomic probe.
The 1.4-kb EcoRl fragment (or the 2 kb-PstI fragment) detected
by this probe is missing in each proband regardless of the extent
of the deletion in COL4A5, and thus can be used to track the
deletion in the kindreds. Conversely, the 1.4-kb EcoRI fragment
and the 2.1-kb PstI fragment detected by Pc4b and containing
COL4A5 exon 51 or exons 49 to 51, respectively, are present in
each proband. Thus, this probe could be used as an internal
control. As expected, the results showed that all the seven
clinically affected women carry the mutation with a reduction in
intensity of the band detected by LA226-EH and a P/C around 0.5
(mean 0.45 0.13), regardless of the probe used as a control. In
all the eight asymptomatic females, the Southern blots of EcoRI
or PstI digests revealed a normal signal with a P/C around I (mean
1.05 0.29; results reported in Table 2). Thus, in six DL-AS
kindreds, we did not observe any female relatives without clinical
symptoms of esophageal tumor who carried the relevant muta-
tion. Similar conclusions were also drawn using a male DNA
sample as control (data not shown).
Moreover, in families BD and RD, densitometry analysis
demonstrated that the affected mothers' DNAs display the muta-
tion whereas the maternal grandmothers' DNAs exhibit a normal
pattern, suggesting a new mutation in the affected mother, given
that the maternal grandfather was obviously clinically unaffected.
In two other families (TP and HL), the deletions were absent in
the DNA from the mother. These results indicate that a new
mutation arose in the two probands, as their respective fathers
were asymptomatic. Thus, de novo mutations were probably found
in four families.
Discussion
We present here the molecular genetic analysis of three novel
DL-AS patients and of fifteen females belonging to six DL-AS
families. By Southern blot analysis, we observed deletions of the
5' ends of both COL4A5 and COL4A6 genes in the three
unrelated DL-AS patients. These data raise to lithe number of
molecular rearrangements characterized in patients with DL-AS
[20, 21]. As we noted previously in other DL-AS patients [21],
these deletions were found to extend only to the two first exons of
COL4A6 in the two male patients. We were not actually able to
characterize the precise extent of the COL4A6 deletions in the
female proband, given the high background obtained with the
JZ3FR145 and JZ3FRI33 probes. Pulsed-field gel electrophoresis
would have been the method of choice to illustrate large DNA
fragments corresponding to both the normal and the mutant
alleles. Unfortunately, agarose-imbedded DNA from these pa-
tients was not available. It is of interest to note that the DL-AS
male patients reported here can be classifed as having juvenile
Alport syndrome. This confirms previous studies showing that AS
patients bearing large rearrangements of COL4A5 are always
severely affected [3]. Indeed, in the patients reported here,
deletions involving the putative promoter region as well as the
first COL4A5 exon can be predicted to be null COL4A5 muta-
tions.
We tracked the mutation in fifteen female relatives belonging to
six families, in order to study the correlation between esophageal
involvement and the mutation, and to determine the penetrance
of DL. Detection of altered-size fragments resulting from the
molecular deletions would have greatly facilitated the determina-
tion of carrier status in females at risk. However, the presence of
the normal allele from the non-mutated X chromosome precludes
diagnosis when analyzing Southern blots [28]. As we did not
detect novel fragments in the DL-AS deletions studied by stan-
dard Southern blotting, we had to use densitometry analysis to
track the mutations, as has been extensively performed in the
diagnosis of female carriers of Duchene muscular dystrophy [29].
All seven female relatives who had displayed digestive symptoms
were shown to carry the deletion, whereas no heterozygous
deletion was detected in the eight clinically unaffected females.
EcoRl/COL4A5 EcoRI/COL4A6
Fig. 2. Southern blots of EcoRl digested DNAs from a control individual
(C), and male patients RD and EQ. A. Hybridization with COL4A5 probe
JZ4. B. Hybridization with a mixture of COL4A6 probes JZ3FR133 and
JZ3FR145.
S.
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Fig. 3. Dosage analysis in females in 6 DL-AS families. Southern blots of digested DNAs were successively hybridized with the genomic probe
LA226-EH, the COL4A5 cDNA probe Pc4b and the rDNA control probe. The variability in the densities of the control bands is mainly due to different
lengths of exposure of the Southern blots. The Southern blot of kindred JT hybridized with Pc4b is not shown. Restriction enzymes used are EcoRI for
kindreds BD, HE, TP, RD, and JT, and PstI for kindred HL. The number at the top of each lane refers to the individual number in Table 1. 1113 in
kindred BD and 1111 in kindred RD refer to unaffected males. M means male control. Patient 12 in family JT died at 48 from a pancreas adenocarcinoma.
In female patients: c esophageal leiomyomatosis, t genital leiomyomatosis, J hematuria renal failure, congenital cataracts. U Alport syndrome,
diffuse esophageal leiomyomatosis and congenital cataracts in male patients.
Furthermore, in the female patients bearing the mutation, the
digestive symptoms were as severe as in their male relatives.
These data suggest that the eosophageal involvement in DL-AS
families segregates as a completely penetrant X-linked dominant
trait, with full expressivity in females, contrary to the renal
disease, in which the penetrance of hematuria in AS females is
thought to range from 0.8 to 1 [4, 301 and symptoms are usually
much less severe than in males. Our results are in agreement with
our previous work which suggests that cell proliferation in DL
could be linked to the dominant effect of an abnormal a6(IV)
chain rather than to the absence of a6(IV) [21].
A surprising feature is the high incidence of de novo mutations
detected in this study. Testing the COL4A5-COL4A6 mutations
in the probands, parents and grandparents when possible, de novo
mutations were found in four of the six families studied. The
mothers of two probands were shown to be noncarriers. In two
other families the maternal grandmothers displayed normal pat-
terns, which suggests that the mutation probably occurred in the
mothers. This is higher than the percentage of new mutations in
Alport syndrome estimated by Shaw and Kallen [31] and found by
Netzer et al [32], which was 18% and 13%, respectively. In our
group, among 40 AS patients with a characterized COL4A5 single
base mutation, de novo mutations were found in six patients and
in two probands' mothers (that is, in 15 to 20%; Knebelman,
manuscript in preparation). The high percentage of de novo
mutations in AS-DL may be due to the occurrence of repeated
sequences in the large COL4A5 and COL4A6 introns, favoring
misalignment.
Finally, we tracked the mutation in a DL female presenting
without any sign of kidney involvement. This patient was accu-
rately investigated, and no biological sign of nephropathy such as
microhematuria could be found. High tone sensorineural deafness
was shown by audiometry in this patient without any other obvious
cause of deafness. Hearing loss in AS carriers has never been
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Table 2. Densitometry values obtained by scanning of the female
relative Southern blots in families with DL-AS
LA226 rDNA R P/C LA226 Pc4b R P/C
Kindred BD
C 7384 1083 6.82 7384 14357 0.51
Ii 6803 1148 5.93 0.87 6803 12990 0.52 1.02
111 2237 745 3.00 0.44 2237 9188 0.24 0.47
1112 6343 1018 6.23 0.91 6343 11362 0.56 1.10
1113 5308 808 6.57 0.96 5308 10429 0.51 1.00
Kindred HE
Cl 2263 3216 0.70 2263 2418 0.94
II 2351 6255 0.38 0.54 2351 5157 0.46 0.49
C2 30708 5278 5.82 N.D.
ILl 3629 1420 2.56 0.44 N.D.
C3 5944 4279 1.39 5944 7371 0.81
1111 757 1409 0.54 0.39 757 2817 0.27 0.33
1112 1424 3169 0.45 0.32 1424 3866 0.37 0.46
Kindred TP
C 4441 1690 2.63 4441 4251 1.04
Ii 3367 1036 3.25 1.24 3367 2400 1.40 1.35
Kindred RD
Cl 11932 12535 0.95 11932 16894 0.71
11 14710 15742 0.93 0.98 14710 17894 0.82 1.15
Ill 6730 16992 0.40 0.42 6730 17841 0.38 0.53
1112 10842 11899 0.91 0.96 10842 14752 0.73 1.03
C2 16578 9618 1.72 16378 7628 2.15
1113 8277 12996 0.64 0.37 8277 8576 0.97 0.45
Kindred iT
C 2788 5243 0.53 9759° 10177° 0.96
12 1031 4247 0.24 0.45 732 1584° 0.46 0.48
112 3623 6994 0.52 0.98 16532° 15700° 1.05 1.09
Kindred ilL
C 9514 11063 0.86 9514 2002 4.75
Ii 26449 23144 1.14 1.33 26449 6230 4.25 0.89
III 7258 15385 0.47 0.55 7258 3110 2.33 0.49
C refers to the female control.
a Densitometry values determined on a second Southern blot not shown
in Figure 2
observed in the absence of renal symptoms [33], but audiometry is
generally not performed in such patients. Cases of DL without
nephropathy have previously been reported in the literature,
either sporadic [34] or familial [35], with or without cataracts
and/or genital involvement [36—38]. Even though cases of isolated
DL clearly transmitted as an autosomal dominant trait have also
been reported [39, 40], it is likely that many of these females might
belong to the AS-DL entity without penetrance of the renal
disease. Here, we have clearly demonstrated that the patient bears
a heterozygous deletion removing at least the first exons of
COL4A5 and COL4A6, and, accordingly, is a carrier of AS. Thus,
isolated DL in female patients can belong to the DL-AS entity.
Such patients have a 50% risk of transmitting severe AS to a male
child, hence the importance of seeking COL4A5-COL4A6 muta-
tions in female patients with DL alone.
Acknowledgments
Parts of this work were presented at the 26th annual meeting of the
American Society of Nephrology, Boston, November 1993 J Am Soc
Nephrol 4:812, 1993). This work was supported by grants from AP-HP,
AURA, MGEN, CNAMTS, the INSERM-CFB agreement, the Associa-
tion Francaise contre les Myopathies, the Association pour Ia Recherche
sur le Cancer and Ia Ligue Nationale Française contre le Cancer. We
thank Drs. C. Geffriaud-Ricouard, C. Kashtan, RA Pagon and R. Hughes-
Benzie for referring the patients, J.P. Bachellerie and K. Tryggvason for
providing the rDNA and the COL4A5 probes, respectively, Mrs. D.
Broneer for aiding in preparation of the manuscript and Drs. E. Boye and
C. Boileau for helpful discussion.
Reprint requests to Dr. Corinne Antignac, INSERM U423, Tour Lavoisier,
6° etage, Hôpital Necker-Enfants Malades, 75743 Paris Cedex 15, France.
References
1. BARKER DF, H05TIKEA SL, Ziiou J, CHOW LT, OLIPHANT AR,
GERKEN SC, GREGORY MC, SKOLNICK MH, ATKIN CL, TRYGGVASON
K: Identification of mutations in the COL4A5 collagen gene in Alport
syndrome. Science 247:1224—1227, 1990
2. TRYOGVASON K, ZHOU J, T-IOSTIKKA SL, SHOWS TB: Molecular
genetics of Alport syndrome. Kidney mt 43:38—44, 1993
3. ANTIGNAC C, KNEBELMANN B, DROUOT L, GRos F, DESCHENES G,
HORS-CAYLA MC, ZHOU J, TRYGGVASON K, GRUNFELD JP, BROYER
M, ET AL: Deletions in the COL4A5 collagen gene in X-linked Alport
syndrome. Characterization of the pathological transcripts in nonrenal
cells and correlation with disease expression. J Clin Invest 93:1195—
1207, 1994
4. ATKIN CL, GREGORY MC, BORDER WA: Alport syndrome, in Diseases
of the Kidney (4th ed), edited by SCHRIER RW, GOTrSCHALK CW,
Boston, Little Brown and Co., 1988, pp 617—641
5. GARCIA TORRES R, GUARNER V: Leiomiomatosis del esophago,
traqueo bronquial y genital asociada con nefropatia hereditaria tipo
Alport: Un nuevo sindrome. Rev GastroenterolMex 48:163—170, 1983
6. ROUSSEL B, BIREMBAUT P, GAILLARD D, PUCHELLE JC, D'ALBIGNAC
G, PENNAFORTE F, FANDRE M: Leiomyomatose oesophagienne famil-
iale associée a un syndrome d'Alport chez on garcon de 9 ans. Helv
PaediatActa 41:359—368, 1986
7. COCHAT P. GUIBAUD P, GARCIA TORRES R, ROUSSEL B, GUARNER V,
LARBRE F: Diffuse leiomyomatosis in Alport syndrome. J Pediatr
113:339—343, 1988
8. LE1CHTER HE, VARGAS J, COHEN AH, AMENT M, SALUSKY IB:
Alport's syndrome and achalasia. Pediatr Nephrol 2:312—314, 1988
9. HASEGAWA 5, SAITOH A, IMAI A, KiKUTA Y, MATSUMOTO Y, OHI R:
A case of non-Alport's hereditary nephritis with esophageal leiomyo-
matosis. Paediatr Nephrol 3:C188, 1989
10. LEBORGNE J, LE NEEL JC, HELOURY Y, AUDOIN AF, DAVID A, BABUT
JM, LENNE Y: La léiomyomatose oesophagienne diffuse. A propos de
5 observations dont 2 cas familiaux. Chirurgie 115:277—286, 1989
II. MCCARTNEY PJ, MCGUINESS R: Alport's syndrome and the eye. Aust
NZJOphtal 17:165—168, 1989
12. WICrIG BM, TREICIIEL U, KOHLER H, RUMPELT HJ, MEYER ZUM
BUSCHENFELDE KH: Leiomyomatose des Gastrointestinal- und Uro-
genitaltrakts in Kombination mit hereditiirer Nephritis. Med Kim
85:122—124, 1990
13. LEGIUS E, PROESMANS W, VAN DAMME B, GEBOES K, LERUT T,
EGGERMONT E: Muscular hypertrophy of the oesophagus and "Al-
port-like" glomerular lesions in a boy. EurJ Pediatr 149:623—627, 1990
14. RABUSI-IKA LS, FISHMAN EK, KUHLMAN JE, HRUBAN RH: Diffuse
esophageal leiomyomatosis in a patient with Alport syndrome: CT
demonstration. Radiology 179:176—178, 1991
15. LERONE M, Donuiso P, ROMEO G, MARTUCCIELLO G, CAFFARENA
PE, BRISIGOT-rI M, TOMA P, TACCONE A, SIIENGO M: Leiomyomatosis
of the oesophagus, congenital cataracts and hematuria. Report of a
case with a rectal involvement. Pediatr Radio! 21:578—579, 1991
16. LONSDAI.E RN, ROBERTS PF, VAUGHAN R, THIRD S: Familial oesoph-
ageal leiomyomatosis and nephropathy. Flistopathology 20:127—133,
1992
17. BLOCH P, QUIJADA 1: Diffuse leiomyomatosis of the esophagus.
Analysis of a case and review of the literature. Gastroenterol C/in Biol
16:890—893, 1992
18. ANTIGNAC C, ZHOU J, SANAK M, COCHAT P, ROUSSEL B, DESCHENES
G, GRos F, KNEBELMANN B, HORS-CAYLA MC, TRYGGVASON K,
GUBLER MC: Alport syndrome and diffuse esophageal leiomyomato-
sis: Deletions in the 5' end of the COL4A5 collagen gene. Kidney mt
42:1178—1183, 1992
19. GARCIA-TORRES R, OROZCO L: Alport-leiomyomatosis syndrome: An
update. Am J Kidney Dis 22:641—648, 1993
20. ZHOU J, MOCHIZUKI T, SMEETS H, ANTIGNAC C, LAURILA P, DE PAEPE
A, TRYGGVASON K, REEDERS ST: Deletion of the paired cs5(IV) and
1906 Dahan et a!: Carrier detection in X-Iinked DL-AS
a6(IV) collagen genes in inherited smooth muscle tumors. Science
261:1167—1169, 1993
21. HEIDET L, DAHAN K, ZHou J, Xu Z, C0cIIAT P, GOULD JDM, LEPPIG
KA, PROESMANS W, GUYOT C, GUILLOT M, ROUSSEL B, TRYGGVASON
K, GRUNFELD JP, GUBLER MC, ANTIGNAC C: Deletions of both
a5(IV) and a6(iv) collagen genes in alport syndrome and in alport
syndrome associated with smooth muscle tumours. Hum Mo! Genet
4:99—108, 1995
22. HEALD J, MOUSSALLI H, HASLETON PS: Diffuse leiomyomatosis of the
oesophagus. Histopatho!ogy 10:755—759, 1986
23. SUGIMOTO M, DOFIASHI T, NIN0MIYA Y: The genes col4a5 and col4a6,
coding for basement membrane collagen chains cs5(IV) and cs6(IV),
are located head-to-head in close proximity on human chromosome
xq22 and col4a6 is transcribed from two alternative promoters. Proc
Nat!Acad Sci USA 91:11679—1 1683, 1994
24. ZHou J, HERTZ JM, LEINONEN A, TRYGGVASON K: Complete amino
acid sequence of the human aS (IV) collagen chain and identification
of a single-base mutation in exon 23 converting glycine 521 in the
collagenous domain to cysteine in an Alport syndrome patient. J Biol
Chem 267:12475—12481, 1992
25. HOSTIKKA SL, EDDY RL, BYERS MG, HOYHTYA M, SHOWS TB,
TRYGGVASON K: Identification of a distinct type IV collagen alpha
chain with restiction kidney distribution and assignment of its gene to
the locus of X-linked Alport syndrome. Proc Nati Acad Sci USA
87:1606—1610, 1990
26. RAYNAL F, MICHOT B, BACHELLERIE JP: Complete nucleotide se-
quence of mouse 18S mRNA gene: Comparison with other available
homologs. FEBS Lett 167:263—266, 1984
27. HENRY I, BONAITI-PELLIE C, CHEHENSSE V, BELDJORD C, SCHWARTZ
C, UTERMANN G, JUNIEN C: Uniparental paternal disomy in a genetic
cancer-predisposing syndrome. Nature 351:665—667, 1991
28. DARRAS BT, BLArrNER P, HARPER JF, SPIRO AJ, ALTER S, FRANCKE
U: Intragenic deletions in 21 Duchenne muscular dystrophy (DMD)/
Becker muscular dystrophy (BMD) families studied with the dystro-
phin eDNA: Location of breakpoints on Hindlil and BglII exon-
containing fragment maps meiotic and mitotic origin of the mutations.
Am J Hum Genet 43:620—629, 1988
29. MAO Y, CREMER M: Detection of Duchenne muscular dystrophy
carriers by dosage analysis using the DMD eDNA clone 8. Hum Genet
81:193—195, 1989
30. FLINTER FA, BOYE E, VETRIE D, HARRIS A: Clinical and molecular
carrier testing for Alport's syndrome in females. Proceedings of the
Third International Workshop on Alport Syndrome, 1994
31. SHAW RF, KALLEN RJ: Population genetics of Alport's syndrome.
Hypothesis of abnormal segregation and the necessary existence of
mutation. Nephron22:15—35, 1976
32. NETZER KO, JUNG C, SEIBOLD 5, RENDERS L, SAARINEN N, ZHOU J,
TRYGGVASON K, WEBER M: Molecular and clinical characterization of
68 families with Alport syndrome. Proceedings of the Third Interna-
tional Workshop on A/port Syndrome, 1994
33. GUBLER MC, LEVY M, BROYER M, NAIZOT C, GONZALES G, PERRIN
D, HABIB R: Alport's syndrome: A report of 58 cases and a review of
the literature. Am J Med 70:493—505, 1981
34. FERNANDES JP, MASCARENHAS MJ, DA COSTA JC, CORREIA JP:
Diffuse leiomyomatosis of the esophagus. A case report and review of
the literature. Dig Dis 20:684—690, 1975
35. WACHSMUTH W: Uber hereditares Vorkommen zirkular wachsender
Leiomyome des Oesophagus. Chiruig 30:145—149, 1959
36. SCHAPIRO RL, SANDROCK AR: Esophagogastric and vulvar leimyoma-
tosis: A new radiologic syndrome. J Can Assoc Radiol 24:184—187,
1973
37. BLANK E, MICHAEL TD: Muscular hypertrophy of the esophagus:
Report of a case with involvement of the entire esophagus. Pediatrics
32:595—598, 1963
38. WAHLEN T, ASTEDT B: Familial occurence of coexisting leiomyoma of
the vulva and oesophagus. .Acta Obstet Gynecol Scand 44:197—203,
1965
39. MARSHALL JB, DIAZ-ARIAS AA, BOCHNA GS, VOGELE KA: Achalasia
due to diffuse esophageal leiomyomatosis and inherited as an autoso-
mal dominant disorder. Report of a family study. Gastroenterology
98:1358—1365, 1990
40. ROSEN RM: Familial multiple upper gastrointestinal leiomyoma.
Gastroenterol 85:303—305, 1990
